What Happened?
Menlo Park, CA-based Geron Promoted Andrew Grethlein as Executive Vice President and Chief Operating Officer
About the Company
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.
About the Person
Andrew J. Grethlein is Executive Vice President and Chief Operating Officer at Geron. Previously, Andrew held various senior IT leadership roles in the industry.
Info Source
News
Short Profile